Introduction
Several phase 1 clinical trials of liposome-mediated gene therapy for cystic fibrosis have been completed and although each study has reported evidence for transgene expression in patients, in all cases the expression has been low and transient. 1 Following our phase 1 trial of delivery of DNA:DOTAP to the nasal epithelia it was apparent that improvements in the efficiency of gene transfer were required. We embarked on a series of studies of gene delivery to the mouse airway epithelium as a model to evaluate the efficiency of in vivo gene delivery protocols. DNA:DOTAP complexes were delivered to the lungs of mice either by intratracheal instillation or by nasal application. Although we could demonstrate reproducible evidence of transgene expression in the lungs of mice this was normally accompanied by an unacceptable level of inflammation/toxicity (McLachlan et al, unpublished) characterised by the presence of focal necrotising inflammation, fibrin leak and neutrophil infiltration in the region of the terminal bronchiole. Similar findings have been reported by other groups. 2 It has recently been reported that instillation of bacterial DNA causes inflammation in the lower respiratory tract of rodents. This was ascribable to the increased number and unmethylated status of bacterial CpG motifs 3 particularly when present in a particular base context. 4 The inflammatory response. It was suggested that the immune system recognises this molecular pattern as 'foreign' thus activating appropriate immune responses. We have found that methylation of DNA decreases the level of several inflammatory cytokines in lavage fluid and surprisingly has a differential effect on expression of the plasmids pCMV CFTR-int6ab and pCMV CAT which only differ in the actual transcription cassette. The severe lung pathology observed did not show a corresponding decrease with methylation suggesting that these cytokines are not the only contributors to the toxicity/inflammation observed. Gene Therapy (2000) 7, 384-392.
response to unmethylated DNA in the lung was originally demonstrated following exposure to heatdenatured (single-stranded) bacterial genomic DNA, which has approximately one motif per 16 base pairs, or to 20 base pair synthetic oligonucleotides containing two CpG motifs. 3 It was suggested that the immune system recognises this molecular pattern as 'foreign' thus activating appropriate immune responses.
The frequency of CpG motifs in the CFTR expression vector used in our studies (pCMV-CFTR-int6ab) is lower (less than one CpG motif per 30 nucleotides) since the human CFTR cDNA contains approximately only onethird of those in the prokaryotic plasmid DNA backbone. CpG motifs in particular base contexts (RRCGYY) have been shown to be the most immunostimulatory (CpG-s motifs) 4 and it is estimated that there is a 20-fold difference between the number of CpG-s sequences in bacterial and mammalian DNA. 4, 5 Of the 265 CpG motifs in pCMV-CFTR-int6ab, 23 fall into this category. Since this vector is produced in bacteria these motifs will not be methylated. A recent study has demonstrated that several cytokines are induced in mouse lungs in response to unmethylated CpG motifs in plasmid DNA and that this is enhanced by lipid. 5 We have investigated whether these DNA motifs exhibit immunostimulatory properties which contribute significantly to the overall inflammatory response observed in our in vivo gene delivery studies.
Results

Cytokine responses
Administration of unmethylated plasmid DNA:DOTAP (UMpDNA:DOTAP) complexes to mouse lungs resulted in a significant increase in the level of the cytokine TNF-␣ in BALF compared with methylated plasmid DNA: DOTAP complexes (MpDNA:DOTAP) (P Ͻ 0.001) at day 1 after administration ( Figure 1) . A further increase in the level of TNF-␣ in BALF of animals treated with UMpDNA:DOTAP was observed at day 2 after administration (although not statistically significant) and also in animals treated with MpDNA:DOTAP (P Ͻ 0.05). These were the only groups whose cytokine levels had increased between day 1 and day 2 and remained significantly elevated above background therefore we extended the study for these two groups to 4 days and 8 days after administration. In animals treated with UMpDNA:DOTAP, the level of TNF-␣ remained elevated at day 4 (P Ͻ 0.05 versus MpDNA:DOTAP) and day 8 (P Ͻ 0.05 versus MpDNA:DOTAP) (Figure 1b ) whereas in animals treated with MpDNA:DOTAP the levels peaked at day 2 then decreased without ever reaching the levels seen with the UMpDNA:DOTAP. These large increases were only observed when pDNA was administered as a complex with DOTAP. DOTAP alone resulted in significantly lower TNF levels (P Ͻ 0.05 at days 1 and 2) and either form of pDNA administered alone resulted in a small initial increase at day 1 but was virtually undetectable at day 2.
Changes in levels of IFN-␥ in BALF were monitored. Levels in animals treated with UMpDNA:DOTAP were significantly higher than those treated with MpDNA:DO-TAP at all time-points except day 2. At day 1 after treatment, the only treatment which resulted in a significant increase in IFN-␥ was UMpDNA:DOTAP ( Figure 2 ) (P Ͻ 0.05 versus MpDNA:DOTAP). The level increased at day 2 (P Ͻ 0.05 versus day 1) as did the IFN-␥ level in BALF from animals treated with MpDNA:DOTAP (P Ͻ 0.05 versus day 1). The elevated levels in BALF from UMpDNA:DOTAP treated animals remained at 4 days (P Ͻ 0.05 versus MpDNA:DOTAP) and although decreased by day 8 (Figure 2b ) remained significant compared with MpDNA:DOTAP (P Ͻ 0.05). Levels in the MpDNA:DO-TAP-treated mice had decreased to barely detectable levels by day 4 and was undetected at day 8. There were no significant increases in IFN-␥ in BALF of animals treated with either form of pDNA alone or with DOTAP alone (Figure 2a) .
Levels of a third cytokine interleukin-6 (IL-6) were also measured in BALF at the various times after administration. Elevated levels of IL-6 were detected in mice treated with either form of pDNA but again only when complexed with DOTAP ( Figure 3 ). The UMpDNA:DO-TAP-treated mice had higher IL-6 in BALF at day 1 (P Ͻ 0.05) and the elevated levels persisted longer (day 4, P Ͻ 0.05) than the MpDNA:DOTAP-treated mice (Figure 3b) . However, the levels of IL-6 in mice treated with DOTAP alone at days 1 and 2, but not animals treated with pDNA alone (no induction observed) were similar to those treated with UMpDNA:DOTAP (Figure 3a) suggesting that the induction of IL6 is primarily due to the DOTAP itself.
Gene Therapy Pathology Despite the differences in cytokine levels between animals treated with UMpDNA:DOTAP and MpDNA:DO-TAP there was no significant difference in the pathology observed in the lungs between the two groups in terms of levels of bronchoalveolar lavage (BAL) neutrophils and macrophages. In both groups there was a large increase in BAL neutrophils at day 1 which decreased with time.
Likewise, histological analysis of sections of lung revealed no obvious difference between the two groups ( Table 1) . Inflammation was observed in both the pDNA:DOTAP groups which was more severe than in animals treated with UMpDNA alone or DOTAP alone and supports the evidence that DOTAP alone is not responsible for the toxicity observed. Lungs sections from these two groups and from DOTAP alone at day 1 were scored blinded for histopathological changes to investigate if there were major differences in the two pDNA: DOTAP groups as a result of the differences in cytokine levels observed. The inflammation was characterised by the presence of focal necrotising inflammation with infiltration of the tissue at these sites initially by large numbers of neutrophils ( Figure 4c ) and to a lesser extent macrophages. Illustrative sections are presented in Figure  4 . Figure 4a is a section from the most severe animal which was treated with UMpDNA:DOTAP, however most of the animals in both groups exhibited regions of pathology similar to Figure 4b but this was not observed in any of the other groups. At later time-points airway exudate in the alveolar regions was more prominent (Figure 4f , g) and clusters of alveolar macrophages were present ( Figure 4h ). There was variation in the severity of inflammation within each group which probably reflects the variable deposition in the different regions of the lung, as well as the variation in efficiency of the delivery method. (Figure 5a ). However, when the methylated plasmid was pre-digested with the methylation-sensitive restriction enzyme HpaII then expression of CAT protein was barely detectable implying that the 30% expression was due to residual unmethylated plasmid DNA (Figure 5b ), and that fully methylated DNA was not expressed. This finding that no expression is seen from fully methylated pCMV-CAT was confirmed in a repeat experiment. RT-PCR analysis of the lung tissue from the in vivo experiments (30 cycles) was performed.
With the intron containing pCMV CFTR-int6ab vector we observed expression of correctly spliced and/or unspliced mRNA. The reason for this is unclear though we are confident that the unspliced size band is RNAderived since we saw no signal in negative control reactions (minus reverse transcriptase). There is no evidence that either form of message is easier to detect than the other. RT-PCR analysis revealed no obvious difference in the number of animals demonstrating expression of transgene-derived CFTR mRNA between groups treated with UMpDNA:DOTAP and MpDNA:DOTAP (Table  2a) . We initially assumed that this was also due to residual unmethylated plasmid. We performed a similar in vitro study in Cos 7 cells using aliquots of the methylated or unmethylated pCMV-CFTR-Int6ab DNA used in the in vivo studies. Expression was analysed by semiquantitative RT-PCR. In this assay samples were subjected to 20, 25 or 30 cycles of PCR and the products assessed by electrophoresis followed by Southern blotting with an internal oligonucleotide. Surprisingly, methylation of this plasmid had no obvious effect on the expression of CFTR mRNA in Cos7 cells as determined by the appearance of the relevant PCR product after an equivalent number of cycles of PCR (Figure 6a ). Furthermore, the expression from the methylated plasmid was not due to residual unmethylated plasmid since digestion with HpaII had no effect on the expression levels observed (Figure 6a iii) and no digested fragments were visible on Southern blot analysis of HpaII-treated plasmid (Figure 6b ). The efficiency of the HpaII digestion was checked on aliquots of unmethylated plasmid which always digested to completion (Figure 6b) . The semiquantitative PCR protocol was subsequently carried out PCR signal in individual animals at day 1 after treatment: 3, seen at 20 cycles; 2, seen at 25 cycles; 1, seen at 30 cycles.
Figure 6 Effect of methylation on expression from pCMV CFTR-int6ab. (a) Detection of pCMV CFTR-int6ab spliced mRNA in Cos7 transfected cells. RT-PCR products removed after 20, 25 and 30 cycles, run on an agarose gel, Southern blotted and probed with an oligonucleotide spanning the exon 6ab splice site (splice oligo) which hybridises to a 177 base pair PCR product. Minus RT analysed after 30 cycles only. (i) UMpCMV CFTR-int6ab:DOTAP; (ii) MpCMV CFTR-int6ab:DOTAP; (iii) MpCMV CFTR-int6ab HpaII digested:DOTAP; (iv) untransfected. (b) Aliquots of the DNA samples transfected into Cos7 cells were run on an agarose gel. Lane 1, UMpCMV CFTR-int6ab undigested; lane 2, UMpCMV CFTR-int6ab HpaII digested; lane 3, MpCMV CFTR-int6ab undigested; lane 4, MpCMV CFTR-int6ab HpaII digested.
Gene Therapy on the tissue samples. No major differences were observed between expression in mice treated with methylated or unmethylated plasmid when all time-points are considered although at day 1 expression of the spliced form of mRNA from methylated plasmid DNA was only observed after 30 cycles suggesting this may be reduced (Table 1b) .
Discussion
We have shown that there is an inflammatory response observed when double-stranded recombinant plasmid DNA/liposome complexes are administered to the lungs of mice in high doses. The results also suggest that this response is due to a combination of DNA and the liposome component rather than to any individual component and that the presence of unmethylated CpG motifs in the plasmid DNA contributes significantly to the overall response. We measured the levels of several pro-inflammatory cytokines in BAL fluid. At day 1 after treatment the level of TNF␣ was significantly raised only in animals treated with UMpDNA:DOTAP. Levels of TNF␣ peaked at day 4 after administration but remained elevated at day 8. This contrasts with the results from Freimark et al 5 where TNF␣ was induced both in animals treated with lipid alone and with lipid:DNA implying that the observed increase in TNF␣ is attributable to the lipid. This difference may be due to the fact that they used a different liposome, namely DOTMA:cholesterol.
A similar pattern was observed for IFN␥. Elevated levels were observed at day 1 only in the UMpDNA:DOTAP group although in the case of IFN␥, levels peaked at day 2 and had fallen close to zero by day 8. A similar result was reported by Freimark et al. 5 The increase in IFN␥ is not merely a consequence of elevated TNF␣ since animals treated with bacterial LPS which show massive induction of TNF␣ at day 1 have barely detectable levels of IFN␥ (data not shown).
Similarly this suggests that the response is not a result of LPS contamination of DNA. Neither of these cytokines are induced by DOTAP alone or by either form of plasmid (UMpDNA or MpDNA) alone. This suggests that it may primarily be a response to intracellular pDNA or else that the rapid degradation of uncomplexed DNA prevents the response occurring. A third pro-inflammatory cytokine IL-6, was measured and was also found to be elevated in BAL. However the levels found in animals treated with DOTAP alone were equivalent to those in the UMpDNA:DOTAP or MpDNA:DOTAP groups indicating that the induction of IL-6 was primarily a response to DOTAP rather than to pDNA. The elevated levels of IL-6 however did appear to persist longer in the UMpDNA:DOTAP group than the MpDNA:DOTAP or DOTAP alone groups. This may simply be a reflection of the difference in the overall inflammatory status of these two groups of animals since this group has elevated levels of both TNF␣ and IFN␥. The levels of both TNF␣ and IFN␥ were elevated at day 1 at which time there was a large number of neutrophils present. This suggested that the neutrophils were a possible source of the cytokines. The paper by Scheule et al 2 reported evidence that neutrophils were the most likely source of TNF␣. In their study the profile of TNF␣ levels matched the BAL neutrophil numbers and antibodies, which prevented neutrophil migration, blocked the increase in TNF␣ but not IL-6. However in this study the cytokines increased at day 2 and peaked at day 4 in contrast to the numbers of BAL neutrophils which was maximal at day 1, decreased at day 2 and again at day 4. This implies that neutrophils may not be the only source of these cytokines.
Methylation of plasmid DNA results in significantly lower levels of inflammatory cytokines in BALF of mice compared with those treated with unmethylated DNA. However, methylation of plasmid DNA for gene therapy applications could have implications for transgene expression since methylation of regulatory regions such as promoters or enhancers may result in silencing of expression. Methylation of the CAT reporter gene plasmid results in a significant decrease in expression to undetectable levels in vitro. However this effect is not observed with the CFTR expression construct either in vitro or in vivo although the semi-quantitative PCR method used cannot rule out smaller decreases in expression. The reason for this difference between plasmids is unclear since the CAT plasmid was derived from the CFTR plasmid by excision of the CFTR cDNA and replacement with the CAT cDNA. It was expected that changes in expression would be related solely to promoter/enhancer sequences which are identical in the two plasmids. Our results suggest that the transcription cassette itself may also be relevant. It may be relevant that the CAT cDNA is bacterial in origin but the CFTR cDNA is mammalian.
Although methylation of bacterial pDNA can significantly reduce the inflammatory cytokine response this appears to have little effect on the lung pathology of treated animals. The severe inflammation/toxicity observed in the UMpDNA:DOTAP group is also seen in the MpDNA:DOTAP animals although it may be that the severe pathology resolves more quickly in the MpDNA: DOTAP animals. Alternatively the variation in delivery and deposition within the lungs may have obscured subtle differences in the histology between the two groups since only one lobe per animal was subjected to histological analysis. It is more likely that other factors involved in the inflammatory cascade in the mice are unaffected by the methylation status of the plasmid DNA and may play a more important role in the overall inflammatory environment. In the period during which this manuscript was under revision a paper was published 6 describing similar studies in mice with analysis at day 1 after administration. They also noted that despite differences in cytokine levels between MpDNA:lipid and UMpDNA:lipid treated animals there was no significant difference in the inflammation score between the two groups when histopathological analysis was performed. Differences were observed in the IL6 response. In their study the IL6 response was only in UMpDNA:lipid-treated animals whereas in our studies the IL6 response appeared to be predominantly due to the lipid. This may be explained by the use of a different liposome preparation (GL67).
This immunostimulatory effect of unmethylated CpG motifs in bacterial DNA contributes to the inflammatory response observed in the lungs of mice and should be considered in studies of gene delivery for CF. Importantly methylation of the CFTR expression plasmid can reduce the induction of several pro-inflammatory cytokines yet unlike the CAT expression plasmid, had no obvious effect on expression levels of CFTR mRNA.
Despite this the lung pathology observed following treatment with methylated plasmid was no less severe than that observed with unmethylated plasmid. This means that the relevance of a methylation step could be questioned and suggests that the severe lung damage is caused by the accumulation of high concentrations of pDNA:liposome complex whether methylated or not. It is possible that complexes may take longer to clear and this could explain why liposome or pDNA alone causes less damage. Alternatively the DNA may have effects through mechanisms other than CpG methylation status. The results also indicate that other factors, such as direct cellular toxicity, as a result of the detergent effects of the lipid, may play a more important role in the overall inflammation/toxicity observed.
Materials and methods
Plasmids pCMV CFTR-int6ab is a modified version of the CFTR cDNA expression construct, pCMV CFTR described previously, 7 which has had the natural CFTR intron6ab sequence restored. pCMV CAT is a modified version of the same plasmid from which the CFTR cDNA sequence was excised and replaced with the bacterial chloramphenicol acetyl transferase (CAT) cDNA. Plasmid DNA was produced by Boehringer Mannheim (Penzberg, Germany) to good manufacturing practice standard as described previously. 8 
Transfection
The transfection reagent used in these studies was DOTAP supplied to us by Boehringer Mannheim. The commercially available formulation (1 mg/ml) was used for in vitro transfection studies in Cos7 cells as described previously. 7 A concentration of 12 mg/ml DOTAP produced to GMP standard was used for the in vivo studies. Cos 7 cell transfections with either pCMV CAT or pCMV CFTR-int6ab were performed in triplicate on at least two separate occasions.
Plasmid methylation pCMV CFTR-int6ab or pCMV CAT plasmid DNA was methylated with SssI CpG methylase (New England Biolabs (UK), Hitchin, UK). Two units of enzyme were used per microgramme of plasmid in the presence of 160 m S-adenosyl methionine (SAM; Sigma, Poole, UK). The reaction was cleaned up by phenol/chloroform extraction.
An aliquot was checked for methylation by restriction digest using HpaII (Boehringer Mannheim) which cuts only unmethylated DNA and Msp I (NEB) which cuts both methylated and unmethylated DNA. The unmethylated DNA used in the studies was subjected to a 'mock methylation' reaction. This was carried out as described above without adding the SssI CpG methylase enzyme. Both plasmids were checked by ethidium bromide staining of an aliquot run out on an agarose gel to ensure comparable concentration before instillation.
Administration of DNA in vivo CD1 mice (Charles River UK, Margate, UK) were anaesthetised by i.p. injection of avertin (0.2 ml per 10 g body weight). The in vivo studies were carried out using pCMV CFTR-int6ab. Methylated or unmethylated plasmid DNA (30 g) either alone or complexed with DOTAP (DNA:DOTAP, 1:12 w/w) was administered to the lungs by intratracheal instillation in a 60 l volume. Control mice were untreated or treated by intratracheal instillation with bacterial lipopolysaccharide (LPS; E. coli 055; B5, Sigma) (40 g).
Cell/tissue harvest and extraction Transfected Cos7 cells were harvested 36-48 h after transfection and either frozen cell pellets were stored for PCR analysis or lysed cell extracts assayed for CAT activity by ELISA (Boehringer Mannheim) as a measure of cell transfection. Mice were killed at selected time-points after administration. Bronchoalveolar lavage (BAL) was performed immediately with 2 × 1 ml volume of sterile PBS via an endotracheal cannula. The lungs were subsequently dissected out and divided. The trachea, large left lobe, right upper lobe and the smallest lower lobe were dissected into pieces and snap frozen in liquid nitrogen for PCR analysis. The two right middle lobes were fixed in 10% neutral buffered formalin for histological analysis.
Analysis of bronchoalveolar lavage fluid (BALF) BALF was centrifuged (5 min at 162 g) and the cell-free supernatant stored in aliquots at −70°C. The BAL cells were resuspended in PBS and cytospins were prepared and stained with Diff-Quick (Gamidor Ltd; product No. 130832, Oxford, UK). Levels of the cytokines TNF-alpha, IFN-gamma and IL-6 in bronchoalveolar lavage fluid (BALF) were measured using mouse immunoassay kits (Genzyme, Framingham, MA, USA) and compared with BALF from untreated animals or animals treated with LPS (40 g).
Histology
Formalin fixed tissues were dehydrated through an alcohol series and xylene and processed to paraffin blocks. 5 m sections were cut at defined sites and stained with a standard haematoxylin and eosin protocol. The lobes were orientated to cut sections in a coronal plane from (1) regions of peripheral lung; (2) regions containing smaller conducting airways; and (3) regions containing major conducting airways. Therefore three section profiles were studied per mouse. At day 1 after treatment three groups (MpDNA:DOTAP, UMpDNA:DOTAP, DOTAP alone) were scored blinded, on a scale of 1 to 5, for certain histopathological features, defined according to specified criteria, and graded. 9 As an example, polymorphonuclear cells were graded according to the following scores. 1: minimal presence of PMNs; 2: excessive PMNs; 3: more widespread PMNs with small foci of PMN accumulation and necrosis; 4: widespread PMNs and larger foci of PMN accumulation and necrosis; 5: widespread PMNs and large areas of PMN accumulation and necrosis.
Immunocytochemistry was performed using a primary antibody raised against 110-kDa Mac-3 antigen (PharMingen, Oxford, UK) expressed on murine mononuclear phagocytes which stains alveolar macrophages with a peroxidase detection system (ABC Peroxidase Kit; Vector, Peterborough, UK).
Gene Therapy
RT-PCR RNA was extracted from lung samples homogenised with a hand held homogeniser (Camlab, Cambridge, UK) or from cell pellets using RNAzol B (Biogenesis, Poole, UK). RNA was DNAse treated using 40 units of DNAse (Boehringer Mannheim) and 10 units of RNAse inhibitor (Boehringer Mannheim) for 60 min at 37°C then cleaned up by phenol/chloroform extraction. First strand cDNA was synthesised from 1 g RNA with a cDNA synthesis kit (Boehringer Mannheim) using poly dT primers. 5 l of cDNA mix was used as a template for RT-PCR. RT-PCR was performed using primers spanning the 6ab intron of CFTR: forward: 5Ј CTT CTG TGG ACT TGG TTT CC (exon 6a); reverse: 5Ј TTC CAT TGC TTC TTC CCA GC (exon 6b); product size: 177 bp, using 200 m dNTPS, 100 ng of each primer, 10% DMSO, 1 × buffer and 0.5 units Taq polymerase (Boehringer Mannheim) at 94°C for 3 min, 55°C for 1 min, 72°C for 1 min for one cycle; 93°C for 30 s, 55°C for 1 min, 72°C for 1 min for 30 cycles. PCR products were removed after 20, 25 and 30 cycles. To check that product was derived from mRNA a minus reverse transcriptase (−RT) control was included for each sample. This consisted of an identical aliquot of RNA processed with cDNA mix which had been preheated to 95°C for 5 min. A separate GAPDH PCR was used as an internal quality control for RNA recovery and integrity. PCR conditions were exactly as above. GAPDH primers: forward: 5Ј TGG AGC CAA AGC GGT CATCA (exon 5); reverse: 5Ј GTG GCA GTG ATG GCA TGG AC (exon 8); product size: 209 bp.
PCR products were analysed on a 1.5% low melting point gel (Gibco BRL, Paisely, UK). Gels were Southern blotted and probed with both an oligo spanning the intron 6a splice site (S1Fix2-splice) which detects spliced message and an oligo contained within the 6a intron (S1Fix2-intron) which detects unspliced message. S1Fix2-splice: 5Ј TGA AGT ACA GAG ATC AGA GA; product size: 177 bp, S1Fix2-intron: 5Ј GGT TTA TGG ATC ATC ACA CC; product size: 1308 bp.
Statistical analysis
In vivo effects of methylated DNA were compared with unmethylated DNA using Kruskal-Wallis analysis of variance followed by pairwise comparison using the Mann-Whitney test.
